{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T07:53:26Z","timestamp":1788940406513,"version":"build-2803163510"},"reference-count":37,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lipidjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1016\/j.jacl.2015.12.024","type":"journal-article","created":{"date-parts":[[2016,1,6]],"date-time":"2016-01-06T18:30:40Z","timestamp":1452105040000},"page":"547-555.e5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"title":["Proprotein convertase subtilisin\/kexin 9 V4I variant with LDLR mutations modifies the phenotype of familial hypercholesterolemia"],"prefix":"10.1016","volume":"10","author":[{"given":"Naotaka","family":"Ohta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mika","family":"Hori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatsune","family":"Ogura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisashi","family":"Makino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamiko","family":"Tamanaha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromi","family":"Fujiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Miyamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariko","family":"Harada-Shiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2015.12.024_bib1","series-title":"The Metabolic and Molecular Bases of Inherited Disease","article-title":"Familial hypercholesterolemia","author":"Goldstein","year":"2001"},{"key":"10.1016\/j.jacl.2015.12.024_bib2","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.atherosclerosis.2010.11.005","article-title":"Molecular genetic epidemiology of homozygous familial hypercholesterolemia in the Hokuriku district of Japan","volume":"214","author":"Mabuchi","year":"2011","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2015.12.024_bib3","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/ncpcardio0836","article-title":"Mechanisms of disease: genetic causes of familial hypercholesterolemia","volume":"4","author":"Soutar","year":"2007","journal-title":"Nat Clin Pract Cardiovasc Med"},{"key":"10.1016\/j.jacl.2015.12.024_bib4","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1210\/jc.2002-021487","article-title":"Clinical features and genetic analysis of autosomal recessive hypercholesterolemia","volume":"88","author":"Harada-Shiba","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jacl.2015.12.024_bib5","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/S0022-2275(20)42605-7","article-title":"Familial defective apolipoprotein B-100: a mutation of apolipoprotein B that causes hypercholesterolemia","volume":"31","author":"Innerarity","year":"1990","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jacl.2015.12.024_bib6","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0021-9150(02)00249-6","article-title":"Molecular genetic analysis of familial hypercholesterolemia: spectrum and regional difference of LDL receptor gene mutations in Japanese population","volume":"165","author":"Yu","year":"2002","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2015.12.024_bib7","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/ng1161","article-title":"Mutations in PCSK9 cause autosomal dominant hypercholesterolemia","volume":"34","author":"Abifadel","year":"2003","journal-title":"Nat Genet"},{"key":"10.1016\/j.jacl.2015.12.024_bib8","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.tibs.2006.12.008","article-title":"Molecular biology of PCSK9: its role in LDL metabolism","volume":"32","author":"Horton","year":"2007","journal-title":"Trends Biochem Sci"},{"key":"10.1016\/j.jacl.2015.12.024_bib9","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa054013","article-title":"Sequence variations in PCSK9, low LDL, and protection against coronary heart disease","volume":"354","author":"Cohen","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2015.12.024_bib10","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1161\/CIRCGENETICS.115.001129","article-title":"Characterization of autosomal dominant hypercholesterolemia caused by PCSK9 gain of function mutations and its specific treatment with alirocumab, a PCSK9 monoclonal antibody","volume":"8","author":"Hopkins","year":"2015","journal-title":"Circ Cardiovasc Genet"},{"key":"10.1016\/j.jacl.2015.12.024_bib11","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/00041433-200204000-00008","article-title":"Phenotypic variability in familial hypercholesterolaemia: an update","volume":"13","author":"Jansen","year":"2002","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.jacl.2015.12.024_bib12","first-page":"I75","article-title":"Genotypic and phenotypic variation in familial hypercholesterolemia","volume":"9","author":"Thompson","year":"1989","journal-title":"Arteriosclerosis"},{"key":"10.1016\/j.jacl.2015.12.024_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2008.06.010","article-title":"Molecular basis of PCSK9 function","volume":"203","author":"Lambert","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2015.12.024_bib14","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1002\/humu.20882","article-title":"Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease","volume":"30","author":"Abifadel","year":"2009","journal-title":"Hum Mutat"},{"key":"10.1016\/j.jacl.2015.12.024_bib15","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.atherosclerosis.2009.11.018","article-title":"The E32K variant of PCSK9 exacerbates the phenotype of familial hypercholesterolaemia by increasing PCSK9 function and concentration in the circulation","volume":"210","author":"Noguchi","year":"2010","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2015.12.024_bib16","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/humu.9383","article-title":"Novel mutations of the PCSK9 gene cause variable phenotype of autosomal dominant hypercholesterolemia","volume":"26","author":"Allard","year":"2005","journal-title":"Hum Mutat"},{"key":"10.1016\/j.jacl.2015.12.024_bib17","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.atherosclerosis.2005.08.015","article-title":"Additive effect of mutations in LDLR and PCSK9 genes on the phenotype of familial hypercholesterolemia","volume":"186","author":"Pisciotta","year":"2006","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2015.12.024_bib18","doi-asserted-by":"crossref","first-page":"E682","DOI":"10.1002\/humu.21002","article-title":"The molecular basis of familial hypercholesterolemia in Lebanon: spectrum of LDLR mutations and role of PCSK9 as a modifier gene","volume":"30","author":"Abifadel","year":"2009","journal-title":"Hum Mutat"},{"key":"10.1016\/j.jacl.2015.12.024_bib19","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.5551\/jat.14621","article-title":"Guidelines for the management of familial hypercholesterolemia","volume":"19","author":"Harada-Shiba","year":"2012","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.jacl.2015.12.024_bib20","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/0021-9150(77)90199-X","article-title":"Discrimination of familial hypercholesterolemia and secondary hypercholesterolemia by Achilles' tendon thickness","volume":"28","author":"Mabuchi","year":"1977","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2015.12.024_bib21","doi-asserted-by":"crossref","first-page":"e100924","DOI":"10.1371\/journal.pone.0100924","article-title":"Large-scale East-Asian eQTL mapping reveals novel candidate genes for LD mapping and the genomic landscape of transcriptional effects of sequence variants","volume":"9","author":"Narahara","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jacl.2015.12.024_bib22","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1111\/j.1469-1809.2008.00436.x","article-title":"Update and analysis of the University College London low density lipoprotein receptor familial hypercholesterolemia database","volume":"72","author":"Leigh","year":"2008","journal-title":"Ann Hum Genet"},{"key":"10.1016\/j.jacl.2015.12.024_bib23","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.atherosclerosis.2014.06.005","article-title":"Genotypic and phenotypic features in homozygous familial hypercholesterolemia caused by proprotein convertase subtilisin\/kexin type 9 (PCSK9) gain-of-function mutation","volume":"236","author":"Mabuchi","year":"2014","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2015.12.024_bib24","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/j.0009-9163.2004.0238.x","article-title":"Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia","volume":"65","author":"Leren","year":"2004","journal-title":"Clin Genet"},{"key":"10.1016\/j.jacl.2015.12.024_bib25","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1093\/hmg\/ddi128","article-title":"Evidence for effect of mutant PCSK9 on apolipoprotein B secretion as the cause of unusually severe dominant hypercholesterolaemia","volume":"14","author":"Sun","year":"2005","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.jacl.2015.12.024_bib26","doi-asserted-by":"crossref","first-page":"E1811","DOI":"10.1002\/humu.21348","article-title":"Molecular spectrum of autosomal dominant hypercholesterolemia in France","volume":"31","author":"Marduel","year":"2010","journal-title":"Hum Mutat"},{"key":"10.1016\/j.jacl.2015.12.024_bib27","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.atherosclerosis.2006.12.035","article-title":"Genetic variants in PCSK9 in the Japanese population: rare genetic variants in PCSK9 might collectively contribute to plasma LDL cholesterol levels in the general population","volume":"196","author":"Miyake","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2015.12.024_bib28","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1002\/humu.20316","article-title":"The c.43_44insCTG variation in PCSK9 is associated with low plasma LDL-cholesterol in a Caucasian population","volume":"27","author":"Yue","year":"2006","journal-title":"Hum Mutat"},{"key":"10.1016\/j.jacl.2015.12.024_bib29","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s10038-003-0114-3","article-title":"Genetic variants in PCSK9 affect the cholesterol level in Japanese","volume":"49","author":"Shioji","year":"2004","journal-title":"J Hum Genet"},{"key":"10.1016\/j.jacl.2015.12.024_bib30","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.numecd.2011.04.003","article-title":"Leucine 10 allelic variant in signal peptide of PCSK9 increases the LDL cholesterol-lowering effect of statins in patients with familial hypercholesterolaemia","volume":"22","author":"Pisciotta","year":"2012","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.jacl.2015.12.024_bib31","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1136\/jmg.2008.059980","article-title":"A PCSK9 variant and familial combined hyperlipidaemia","volume":"45","author":"Abifadel","year":"2008","journal-title":"J Med Genet"},{"key":"10.1016\/j.jacl.2015.12.024_bib32","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/0021-9150(96)05907-2","article-title":"Heterozygous familial hypercholesterolemia in children: low-density lipoprotein receptor mutational analysis and variation in the expression of plasma lipoprotein-lipid concentrations","volume":"126","author":"Torres","year":"1996","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2015.12.024_bib33","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.atherosclerosis.2008.07.005","article-title":"Update of Japanese common LDLR gene mutations and their phenotypes: Mild type mutation L547V might predominate in the Japanese population","volume":"203","author":"Miyake","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2015.12.024_bib34","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.1172\/JCI45504","article-title":"The N342S MYLIP polymorphism is associated with high total cholesterol and increased LDL receptor degradation in humans","volume":"121","author":"Weissglas-Volkov","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jacl.2015.12.024_bib35","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1161\/CIRCRESAHA.115.304660","article-title":"Mutations in STAP1 are associated with autosomal dominant hypercholesterolemia","volume":"115","author":"Fouchier","year":"2014","journal-title":"Circ Res"},{"key":"10.1016\/j.jacl.2015.12.024_bib36","doi-asserted-by":"crossref","first-page":"E41","DOI":"10.1210\/jc.2014-3066","article-title":"Removal of plasma mature and furin-cleaved proprotein convertase subtilisin\/kexin 9 by low-density lipoprotein-apheresis in familial hypercholesterolemia: development and application of a new assay for PCSK9","volume":"100","author":"Hori","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jacl.2015.12.024_bib37","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/1471-2350-11-115","article-title":"Genomic characterization of large rearrangements of the LDLR gene in Czech patients with familial hypercholesterolemia","volume":"11","author":"Goldmann","year":"2010","journal-title":"BMC Med Genet"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287415300726?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287415300726?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T01:57:28Z","timestamp":1654048648000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287415300726"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["S1933287415300726"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2015.12.024","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Proprotein convertase subtilisin\/kexin 9 V4I variant with LDLR mutations modifies the phenotype of familial hypercholesterolemia","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2015.12.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 National Lipid Association. All rights reserved.","name":"copyright","label":"Copyright"}]}}